Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,578 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Juvenile-Onset Diabetes Clear all
Recruiting Phase 1Phase 2 Interventional

Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes

NCT03746769
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogenic Human Islet Cells, Gastrin 17
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Early Phase 1 Interventional

Diabetes Inspired Culinary Education

NCT05160142
View directory record Official record
Conditions
Type I Diabetes
Interventions
DICE
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Phase 3 Interventional

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

NCT00115570
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Insulin glulisine, insulin lispro, insulin glargine, NPH insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 17 Years
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

NCT01839370
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed Loop with Pramlintide
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2014 · Synced Sep 25, 2026, 5:45 AM EDT
Terminated Phase 2 Interventional

Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

NCT06007508
View directory record Official record
Conditions
DKA
Interventions
Insulin Glargine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms

NCT02438189
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Predictive Hyperglycemia Minimization Algorithm, Predictive Hypoglycemia Minimization Algorithm
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
15 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 25, 2026, 5:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes

NCT00727220
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
1 Year to 5 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 25, 2026, 5:45 AM EDT
Withdrawn Phase 2 Interventional

Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)

NCT03794973
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
TOL-3021, TOL-3021 Placebo
Biological · Other
Lead sponsor
Tolerion, Inc.
Industry
Eligibility
12 Years to 35 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 25, 2026, 5:45 AM EDT
Terminated Phase 3 Interventional

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

NCT00751842
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
rhGAD65, Placebo
Drug
Lead sponsor
Diamyd Therapeutics AB
Industry
Eligibility
10 Years to 20 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
43
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2012 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Mind-Body Intervention for Diabetes Management: A Pilot Study

NCT04944264
View directory record Official record
Conditions
Diabetes Mellitus, Stress, Psychological, Stress, Physiological
Interventions
Stress Management and Resiliency Training (SMART) program
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Overcoming Barriers and Obstacles to Adopting Diabetes Devices

NCT04161131
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ONBOARD
Behavioral
Lead sponsor
Molly Tanenbaum
Other
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of TTP399 in Patients With Type 1 Diabetes

NCT03335371
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
TTP399, Placebo Oral Tablet
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
15
States / cities
Beverly Hills, California • Escondido, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 25, 2026, 5:45 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

NCT06609356
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes, Healthy Volunteer
Interventions
Study Visit 1, Placebo, Study Visit 2, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Phase 1 Interventional Results available

Hyaluronidase Effect on Infusion Set Life

NCT02199028
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hyaluronidase, Control
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Sep 25, 2026, 5:45 AM EDT
Recruiting Phase 2 Interventional

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

NCT05414409
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Metformin
Drug
Lead sponsor
Heba M. Ismail
Other
Eligibility
11 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

NCT01928329
View directory record Official record
Conditions
Type I Diabetes
Interventions
Exenatide (Bydureon®), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes

NCT05403502
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
t:slim X2 insulin pump with Control-IQ technology 1.5
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
6 Years to 80 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
13
States / cities
Orange, California • Palo Alto, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Not applicable Interventional

Home-Based Interventions for Adolescents With Type 1 Diabetes

NCT02243072
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Fit Families plus Standard Medical Care
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 25, 2026, 5:45 AM EDT
Terminated Phase 1 Interventional Results available

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

NCT02716805
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Tremelimumab, Durvalumab, Prevnar-13, Melphalan
Drug · Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 25, 2026, 5:45 AM EDT
No Longer Available No phase listed Expanded access

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

NCT01309022
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Sirolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
U.S. locations
3
States / cities
Miami, Florida • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 25, 2026, 5:45 AM EDT
Recruiting No phase listed Observational

Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics

NCT06401577
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
Dexcom Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

ACCESS: AI for pediatriC diabetiC Eye examS Study

NCT05131451
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Point of Care Autonomous AI diabetic retinopathy exam
Diagnostic Test
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 21 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Not applicable Interventional Results available

Closed-Loop Insulin Delivery in Children Less Than 7 Years of Age

NCT01421225
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Closed-loop Insulin Pump therapy, Standard Insulin Pump Therapy
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months to 7 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 25, 2026, 5:45 AM EDT
Completed Phase 4 Interventional Results available

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis

NCT02078882
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
abatacept
Biological
Lead sponsor
Christopher Bowlus, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 25, 2026, 5:45 AM EDT